Marshall Wace North America’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Marshall Wace North America’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-58,094	Closed	-$1.15M	–	1749
2019 Q4	$1.15M	Buy	58,094 +57,384	+8,082%	+$918K	0.01%	693
2019 Q3	$9K	Buy	+710	New	+$8.57K	﹤0.01%	1265
2019 Q2	–	Sell	-8,947	Closed	-$130K	–	1829
2019 Q1	$130K	Buy	+8,947	New	+$114K	﹤0.01%	1067

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Marshall Wace North America's MNTA Position: Q1 2020 in Review

Marshall Wace North America sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2020, closing a stake of 58,094 shares — an estimated $1.15M sold.

Marshall Wace North America first reported a position in MNTA in Q1 2019 and held it in 3 quarters. The position peaked at $1.15M in Q4 2019. 199 funds tracked by Wall St. Rank hold MNTA as of Q1 2020.

Marshall Wace North America reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Marshall Wace North America sold 58,094 Momenta Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1.15M.
Marshall Wace North America first reported a position in Momenta Pharmaceuticals, Inc. in Q1 2019 and held it in 3 quarters.
Marshall Wace North America's Momenta Pharmaceuticals, Inc. position peaked at $1.15M in Q4 2019.
199 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.